AAAAAA
Results:
1-17
|
Results: 17
Authors:
Guichard, S
Montazeri, A
Chatelut, E
Hennebelle, I
Bugat, R
Canal, P
Citation: S. Guichard et al., Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: Pharmacokinetic and pharmacodynamic evaluation, CLIN CANC R, 7(10), 2001, pp. 3222-3228
Authors:
Guichard, S
Arnould, S
Hennebelle, I
Bugat, R
Canal, P
Citation: S. Guichard et al., Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo, ANTI-CANC D, 12(9), 2001, pp. 741-751
Authors:
Seronie-Vivien, S
Mery, E
Delord, JP
Fillola, G
Tkaczuk, J
Voigt, JJ
Bugat, R
Citation: S. Seronie-vivien et al., Carcinocythemia as the single extension of breast cancer: Report of a caseand review of the literature, ANN ONCOL, 12(7), 2001, pp. 1019-1022
Authors:
Oudard, S
Caty, A
Humblet, Y
Beauduin, M
Suc, E
Piccart, M
Rolland, F
Fumoleau, P
Bugat, R
Houyau, P
Monnier, A
Sun, X
Montcuquet, P
Breza, J
Novak, J
Gil, T
Chopin, D
Citation: S. Oudard et al., Phase II study of vinorelbine in patients with androgen-independent prostate cancer, ANN ONCOL, 12(6), 2001, pp. 847-852
Authors:
Van Cutsem, E
Twelves, C
Cassidy, J
Allman, D
Bajetta, E
Boyer, M
Bugat, R
Findlay, M
Frings, S
Jahn, M
McKendrick, J
Osterwalder, B
Perez-Manga, G
Rosso, R
Rougier, P
Schmiegel, WH
Seitz, JF
Thompson, P
Vieitez, JM
Weitzel, C
Harper, P
Citation: E. Van Cutsem et al., Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study, J CL ONCOL, 19(21), 2001, pp. 4097-4106
Authors:
Bugat, R
Citation: R. Bugat, Oxaliplatin: safety profile in metastatic colorectal cancer, B CANCER, 88, 2001, pp. S45-S49
Authors:
Hennebelle, I
Terret, C
Chatelut, E
Bugat, R
Canal, P
Guichard, S
Citation: I. Hennebelle et al., Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitra-phenylacetate converting carboxylesterase activity, ANTI-CANC D, 11(6), 2000, pp. 465-470
Authors:
Montazeri, A
Boucaud, M
Lokiec, F
Pinguet, F
Culine, S
Deporte-Fety, R
Albin, N
Laguerre, B
Goupil, A
Bugat, R
Canal, P
Chatelut, E
Citation: A. Montazeri et al., Population pharmacokinetics of topotecan: intraindividual variability in total drug, CANC CHEMOT, 46(5), 2000, pp. 375-381
Authors:
Guimbaud, R
Guichard, S
Dusseau, C
Bertrand, V
Aparicio, T
Lochon, I
Chatelut, E
Couturier, D
Bugat, R
Chaussade, S
Canal, P
Citation: R. Guimbaud et al., Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans, CANC CHEMOT, 45(6), 2000, pp. 477-482
Authors:
Terret, C
Erdociain, E
Guimbaud, R
Boisdron-Celle, M
McLeod, HL
Fety-Deporte, R
Lafont, T
Gamelin, E
Bugat, R
Canal, P
Chatelut, E
Citation: C. Terret et al., Dose and time dependencies of 5-fluorouracil pharmacokinetics, CLIN PHARM, 68(3), 2000, pp. 270-279
Authors:
Chatelut, E
Canal, P
Bugat, R
Citation: E. Chatelut et al., Pharmacokinetics and dose adjustment of carboplatin, B CANCER, 87, 2000, pp. 17-23
Authors:
Freyer, G
Rougier, P
Bugat, R
Droz, JP
Marty, M
Bleiberg, H
Mignard, D
Awad, L
Herait, P
Culine, S
Trillet-Lenoir, V
Citation: G. Freyer et al., Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure, BR J CANC, 83(4), 2000, pp. 431-437
Authors:
Gladieff, L
Chatelut, E
Gaspard, MH
Skaf, R
de Forni, M
Mihura, J
Canal, P
Bugat, R
Citation: L. Gladieff et al., Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study, B CANCER, 86(7-8), 1999, pp. 673-677
Authors:
Kurtz, JE
Trillet-Lenoir, V
Bugat, R
Negrier, S
Adenis, A
Kayitalire, L
Ripoche, V
Dufour, P
Citation: Je. Kurtz et al., Compassionate use of gemcitabine in advanced pancreatic cancer: a French multicentric study, B CANCER, 86(2), 1999, pp. 202-206
Authors:
Guichard, S
Terret, C
Hennebelle, I
Lochon, I
Chevreau, P
Fretigny, E
Selves, J
Chatelut, E
Bugat, R
Canal, P
Citation: S. Guichard et al., CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues, BR J CANC, 80(3-4), 1999, pp. 364-370
Authors:
Friedlander, M
Millward, MJ
Bell, D
Bugat, R
Harnett, P
Moreno, JA
Campbell, L
Varette, C
Ripoche, V
Kayitalire, L
Citation: M. Friedlander et al., A phase II study of Gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer, ANN ONCOL, 9(12), 1998, pp. 1343-1345
Authors:
Bugat, R
Citation: R. Bugat, Topoisomerase inhibitors. 1. New indications, EUROCANCER 98, 1998, pp. 201-202
Risultati:
1-17
|